CJC-1295 + Ipamorelin 10+10mg

What is CJC-1295 + Ipamorelin ?

CJC-1295 + Ipamorelin 10+10mg is a pre-blended vial holding 10mg of CJC-1295 without DAC and 10mg of ipamorelin, 20mg of lyophilised peptide in total. It is also written CJC1295/ipamorelin. The larger vial suits longer series than the 5+5mg blend.

CJC-1295 without DAC, also called modified GRF (1-29), is a GHRH (1-29) analogue with four substitutions. It acts at the GHRH receptor on pituitary somatotrophs. Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH₂, a selective agonist at the ghrelin receptor, GHS-R1a. The two receptors sit on the same cell but signal differently, which is why the pair is the standard two-receptor design in growth hormone release research.

Equal mass is far from equal moles. At 3367.9 and 711.9 g/mol, 10mg of each is about 3.0 µmol of CJC-1295 against 14.0 µmol of ipamorelin, roughly 4.7 to 1 in favour of ipamorelin.

CJC-1295 + Ipamorelin Research Applications

• Two-receptor design : in 18 men, a GH-releasing peptide plus GHRH gave a greater-than-additive growth hormone response (Bowers et al., 1990).
• Ipamorelin selectivity : in swine it released growth hormone without raising ACTH or cortisol beyond GHRH levels, unlike GHRP-6 and GHRP-2 (Raun et al., Eur J Endocrinol, 1998).
• The receptor : GHS-R1a was cloned from pituitary and hypothalamus and shown to be the target of synthetic secretagogues (Howard et al., Science, 1996).
• CJC-1295 human data : Teichman and colleagues (2006) studied the long-acting DAC form, not the no-DAC peptide in this vial.

Typical preclinical uses are dual-receptor somatotroph stimulation, pulsatile growth hormone release kinetics with both inputs applied together, and downstream IGF-1 axis work. The fixed mass ratio removes ratio-preparation error, and one batch covers a whole replicate series.

CJC-1295 + Ipamorelin 10+10mg vs the 5+5mg Presentation

The two vials are the same blend at different mass. Both hold the peptides at a 1:1 mass ratio, so a design built on the 5+5mg vial transfers without any change in stoichiometry. The 10+10mg vial holds 20mg in total. That means fewer vials and reconstitutions across a replicate series, and one certificate covering more material. Designs that need independent concentrations, a single-agent control arm or attribution to one receptor need the separate vials.

Research Overview

This is a single lyophilised vial co-formulating two growth hormone secretagogues at higher mass than the original format: CJC-1295 10mg and Ipamorelin 10mg, 20mg of total peptide per vial. CJC-1295 is a modified GHRH(1-29) analogue (CAS 863288-34-0, 3647.8 g/mol) that signals at the GHRH receptor on the pituitary somatotroph, while Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂, CAS 170851-70-4, 711.85 g/mol) acting as a selective agonist at the ghrelin receptor GHS-R1a. The two receptors converge on the same cell through different second-messenger pathways, which is why the two classes are frequently co-studied for complementary signalling rather than treated as alternatives to one another.

The pairing rests on two separate single-agent literatures plus a general synergy literature. On the GHRH side, the defining human pharmacology is Teichman and colleagues (J Clin Endocrinol Metab, 2006), who reported dose-dependent increases in plasma growth hormone and IGF-I after CJC-1295 in healthy adults. On the ghrelin side, Raun and colleagues (Eur J Endocrinol, 1998) characterised Ipamorelin as the first growth hormone secretagogue with selectivity for growth hormone release approaching that of GHRH itself, without the ACTH and cortisol elevation seen with earlier compounds in the class. The receptor itself was cloned and shown to be the target of the synthetic secretagogues by Howard and colleagues (Science, 1996). Class-level combination designs trace to Bowers and colleagues (J Clin Endocrinol Metab, 1990), who showed a GHRP acting with GHRH produced a greater combined response than either alone.

The 10+10mg presentation differs from the 5+5mg vial in mass per vial, not in chemistry. Both carry the components at a fixed 1:1 mass ratio, which is far from equimolar: the GHRH analogue is the larger molecule, so each vial holds roughly 14 µmol of ipamorelin against 2.7 µmol of CJC-1295. Doubling the mass doubles both sides of that ratio, leaving the stoichiometry unchanged; what the larger format changes is laboratory logistics, one vial covering longer replicate series with one batch and one certificate. The honest caveat is unchanged as well: no controlled study of this specific blend has been published.

Storage and Reconstitution

Keep sealed vials at -20°C, away from light and moisture. After reconstitution, keep the solution at 2-8°C and use it within 4 weeks, or freeze single-use aliquots at -20°C. The GHRH analogue is the less stable partner and sets the in-use window for the whole vial, so aliquot at reconstitution.

Vials are sold on their own, without bacteriostatic water for mixing or other supplies.

How to reconstitute and handle

Treat the vial as one 20mg preparation, with the fill volume set by the concentration your protocol needs. Let the vial and the bacteriostatic water reach room temperature and swab both stoppers. Add the water slowly down the inside wall and swirl gently until dissolved. Do not shake or vortex: the GHRH-class peptide is the shear-sensitive partner. The solution should be clear and colourless. The peptides cannot be separated afterwards. Label the vial with fill volume, concentration and date.

• Both components are in the same vial and go into solution together, so the blend cannot be separated after reconstitution. The equal-mass mix is far from equimolar, roughly 14 µmol of ipamorelin to 2.7 µmol of CJC-1295 per vial.

For the full method, see the peptide reconstitution guide and the reconstitution calculator.

Research References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman et al., J Clin Endocrinol Metab, 2006; DAC form)
• Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol, 1998)
• Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone (Bowers et al., J Clin Endocrinol Metab, 1990)
• A receptor in pituitary and hypothalamus that functions in growth hormone release (Howard et al., Science, 1996)

Published research on CJC-1295 + Ipamorelin is indexed on PubMed.